Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nadolol/Bendroflumethiazide · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg |
| 2 | ACTIVE_COMPARATOR | Corzide® Tablets 80 mg/5 mg |
| Name | Type | Description |
|---|---|---|
| Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg | DRUG | 80/5mg, single dose fed |
| Corzide® Tablets 80 mg/5 mg | DRUG | 80/5mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (β-HCG) pregnancy tests performed within 21 days prior to the start of the study and on the evening...
Nadolol/Bendroflumethiazide is a combination small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with studies evaluating the fasting and fed state pharmacokinetics of the 80 mg/5 mg tablet formulation. The drug is being developed by Viatris Inc. (VTRS).
Nadolol/Bendroflumethiazide is being developed by Viatris Inc., a global healthcare company traded on the NASDAQ under the ticker VTRS. The company is conducting Phase 1 clinical trials to evaluate the drug's pharmacokinetic profile in healthy adult volunteers.
Nadolol/Bendroflumethiazide is in Phase 1 clinical development. Two Phase 1 studies have been completed, both involving healthy volunteers. The drug is investigational and has not been approved by regulatory authorities for any indication.
Nadolol/Bendroflumethiazide has two completed Phase 1 trials. NCT00647660 is a fasting study comparing the 80 mg/5 mg tablet to Corzide tablets, enrolling 66 participants. NCT00648297 is a fed study with the same comparison, enrolling 42 participants. Both were conducted in the United States.
Nadolol/Bendroflumethiazide is being studied as a generic equivalent to Corzide tablets. The Phase 1 trials compare the pharmacokinetics of the 80 mg/5 mg Nadolol/Bendroflumethiazide tablet to Corzide 80 mg/5 mg tablets in healthy volunteers under fasting and fed conditions.